The KAT7 Knockout TE1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the KAT7 gene in the human esophageal squamous cell carcinoma line TE1. This loss-of-function model enables systematic exploration of KAT7-dependent molecular pathways without clonal selection artifacts, providing a heterogeneous population that mimics natural genetic variation. The polyclonal format is particularly suited for pooled functional screens and population-level analyses of gene disruption effects.
The TE1 parental line is an adherent, epithelial-like cell line derived from human esophageal squamous cell carcinoma (Homo sapiens). These cells maintain key characteristics of esophageal cancer, including dysregulated proliferation and altered DNA damage responses, making them a relevant in vitro model for studying oncogenic processes. The TE1 background offers a platform to examine tumor-specific functions of KAT7 in the context of esophageal squamous cell carcinoma, a malignancy with limited therapeutic options.
KAT7 encodes a histone acetyltransferase that catalyzes acetylation of histone H3 and H4, primarily at replication origins, to facilitate the loading of the MCM2-7 helicase complex during origin licensing. This activity is regulated by upstream factors including CDK2, ING5, EAF6, and MEAF6, and is essential for DNA replication initiation. KAT7 also participates in the DNA damage response by promoting local histone acetylation to enable repair factor access. It interacts with multiple partner proteins such as ING5, EAF6, MEAF6, JADE1, BRPF1, ORC1, CDC6, and CDT1 to form functional complexes. Downstream, KAT7-mediated acetylation influences expression of replication-related genes, including c-MYC, and modulates origin firing efficiency. Thus, KAT7 integrates cell cycle signals and DNA damage cues to coordinate replication and genome maintenance.
In the TE1 esophageal cancer model, disruption of KAT7 is predicted to compromise origin licensing and DNA replication fidelity, potentially leading to replication stress and genomic instability??hallmarks of cancer. The knockout cells offer a unique tool to dissect how KAT7-dependent acetylation impacts tumor cell proliferation, survival, and response to genotoxic agents commonly used in chemotherapy. By bridging histone modification and cancer phenotype, this model facilitates mechanistic studies into epigenetic dysregulation in esophageal squamous cell carcinoma and enables evaluation of KAT7 as a therapeutic vulnerability.
Researchers can employ this polyclonal knockout population in a variety of assays to probe KAT7 function. Chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) can assess changes in histone H3/H4 acetylation at specific loci, while Western blotting and RT-qPCR verify protein and transcript levels of KAT7 targets. Cell cycle distributions are readily analyzed by flow cytometry, and DNA replication dynamics may be monitored via EdU incorporation. DNA damage accumulation can be evaluated by comet assays or ??H2AX staining. Functional studies using colony formation, migration, and proliferation assays help define the role of KAT7 in cancer cell behavior. Additionally, the cells support drug target validation by testing sensitivity to inhibitors or chemotherapeutics. For further details or to discuss custom genome engineering services, please contact Ascent Research.
